In Vivo Efficacy of a Macrocyclic Peptoid‐Peptide Hybrid That Selectively Modulates the Beta‐Catenin/TCF Interaction to Inhibit Prostate Cancer
Our findings underscore the therapeutic potential of peptoid-peptide macrocycle inhibition of β-catenin in prostate cancer.
Authors
- Jill E. Schneider (ORCID: https://orcid.org/0009-0000-3013-3582)
- Maud Voisin
- Susan K. Logan (ORCID: https://orcid.org/0000-0002-7904-5927)
- Kwok‐Kin Wong (ORCID: https://orcid.org/0000-0001-6323-235X)
- Susan Ha (ORCID: https://orcid.org/0009-0006-7287-9300)
- J. Campos Franco (ORCID: https://orcid.org/0000-0003-1629-5424)
- Kent Kirshenbaum (ORCID: https://orcid.org/0000-0003-0426-2772)
- Justine Habault (ORCID: https://orcid.org/0000-0001-6375-6428)
- Michael J. Garabedian (ORCID: https://orcid.org/0000-0001-8915-7378)
- David R. Wise (ORCID: https://orcid.org/0000-0003-3419-4723)
Institutions
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center
- New York University (US)
Publication Details
- Journal
- The Prostate
- Published
- 2025-02-16
- DOI
- https://doi.org/10.1002/pros.24868
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52